|
|
|
|
| LEADER |
01425nam a2200325 u 4500 |
| 001 |
EB001999452 |
| 003 |
EBX01000000000000001162353 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Marchand, Dave K.
|
| 245 |
0 |
0 |
|a Duration of bisphosphonate treatment for patients with osteoporosis
|h Elektronische Ressource
|b a review of clinical effectiveness and guidelines
|c Dave Marchand, Hannah Loshak
|
| 246 |
3 |
1 |
|a Duration of BIS treatment for patients with osteoporosis
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2019, October 4, 2019
|
| 300 |
|
|
|a 1 PDF file (52 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Osteoporosis / drug therapy
|
| 653 |
|
|
|a Bone Density Conservation Agents
|
| 653 |
|
|
|a Diphosphonates / therapeutic use
|
| 653 |
|
|
|a Duration of Therapy
|
| 700 |
1 |
|
|a Loshak, Hannah
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK551872
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|